{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-23-000094","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.563304+00:00","generated_at":"2026-06-09T22:53:00.799360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"JNJ Q3 adjusted EPS $2.66 rises 19% YoY; $21.7B gain from Kenvue separation","bullets":["Q3 sales $21.35B (+6.8% YoY); adjusted diluted EPS $2.66 (+19.3% YoY from $2.23).","Innovative Medicine revenue $13.89B (+5.1% reported); MedTech $7.46B (+10.0%).","U.S. sales grew 11.1% to $11.996B; international sales rose 1.6% to $9.355B.","Discontinued ops net earnings $21.7B (incl. gain from Kenvue separation) vs $148M prior year.","Adjusted pretax income from continuing ops $8.03B, up 13.8% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-23-000094","json":"https://secwatch.observer/filing/0000200406-23-000094.json","markdown":"https://secwatch.observer/filing/0000200406-23-000094.md","text":"https://secwatch.observer/filing/0000200406-23-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000094/0000200406-23-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000094/jnj-20231017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:53:00.799360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}